New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing

Current Opinion in Hematology

Volumn 21, Issue 4, 2014, Pages 326-332

  Greenough, Adrienne ^a,b   Dave, Sandeep S ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Burkitt lymphoma; ID3; MYC

Indexed keywords

BRG1 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF DIFFERENTIATION 3; INITIATION FACTOR 4B; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTOME;

BRG1 GENE; BURKITT LYMPHOMA; BURKITT LYMPHOMA CELL LINE; CANCER RISK; CANCER SURVIVAL; CCND3 GENE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 18Q; CHROMOSOME 19P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 4Q; CHROMOSOME 9Q; CHROMOSOME DELETION; CHROMOSOME XQ; COPY NUMBER VARIATION; DDX3X GENE; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; GAB1 GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TRANSLOCATION; GERMINAL CENTER; GNA 13 GENE; GNA13 GENE; HUMAN; IN SITU HYBRIDIZATION; INHIBITOR OF DIFFERENTIATION 3 GENE; INITIATION FACTOR 4B GENE; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; LYMPHOMA CELL; MASCULINITY; MOLECULAR PATHOLOGY; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; ROCK1 GENE; TP 53 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; ONCOGENE MYC;

ANIMALS; BURKITT LYMPHOMA; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; GENES, MYC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; MUTATION; TRANSCRIPTOME; TRANSLOCATION, GENETIC;

EID: 84902290001     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000059     Document Type: Review

References (56)

1. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 1982; 79:7837-7841.
2. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46:218-223.
3. Shiels MS, Engels EA, Linet MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992- 2009. Cancer Epidemiol Biomarkers Prev 2013; 22:1069-1078.
4. Mbulaiteye SM, Biggar RJ, Bhatia K, et al. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer 2009; 53:366-370.
5. Burkitt D, OConor G. Malignant lymphoma in African children. I. A clinical syndrome. Cancer 1961; 14:258-269.
6. Oconor G. Malignant lymphoma in African children. II. A pathological entity. Cancer 1961; 14:270-283.
7. Aka P, Vila MC, Jariwala A, et al. Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response. Blood 2013; 122:629-635.
8. Johnston WT, Mutalima N, Sun D, et al. Relationship between Plasmodium falciparum malaria prevalence, genetic diversity and endemic Burkitt lymphoma in Malawi. Sci Rep 2014; 4:3741.
9. Epstein MA, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitts lymphoma. Lancet 1964; 283:702-703.
10. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008; 123:2658-2663.
11. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the surveillance, epidemiology, and end results database. Cancer 2013; 119:3672-3679.
12. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265-276.
13. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724-3734.
14. Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIVinfected patients: from pathogenesis to pathology. Semin Cancer Biol 2013; 23:457-467.
15. Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010; 116:5600-5604.
16. Mbulaiteye SM, Pullarkat ST, Nathwani BN, et al. Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979-2009. APMIS 2014; 122:5-15.
17. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitts lymphoma. N Engl J Med 2006; 354:2431-2442.
18. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009; 113: 4586-4594.
19. Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 2011; 117:3596-3608.
20. Victora GD, Dominguez-Sola D, Holmes AB, et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 2012; 120:2240-2248.
21. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012; 22:167-179.
22. Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011; 25:1869-1876.
23. Onnis A, De Falco G, Antonicelli G, et al. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 2010; 5:e12960.
24. Zhao X, Lwin T, Zhang X, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogencity. Leukemia 2013; 27:2341-2350.
25. Jin HY, Oda H, Lai M, et al. MicroRNA-17+92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J 2013; 32:2377-2391.
26. Olive V, Sabio E, Bennett MJ, et al. A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife 2013; 2:e00822.
27. Psathas JN, Doonan PJ, Raman P, et al. The Myc-miR-17-92 axis amplifies Bcell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood 2013; 122:4220-4229.
28. Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair 2006; 5:1213-1224.
29. Buckle GC, Collins JP, Sumba PO, et al. Factors influencing time to diagnosis and initiation of treatment of endemic Burkitt lymphoma among children in Uganda and western Kenya: a cross-sectional survey. Infect Agent Cancer 2013; 8:36.
30. Burmeister T, Molkentin M, Schwartz S, et al. Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma. Mol Oncol 2013; 7:850-858.
31. Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014; 123:1187-1198.
32. Pedersen M, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC-or double-hit MYC/BCL2 translocations. Eur J Haematol 2014; 92:42-48.
33. Snuderl M, Kolman OK, Chen Y-B, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34:327-340.
34. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@ BCL2/t (14; 18)(q32; q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012; 25:145-156.
35. Aukema SM, Kreuz M, Kohler CW, et al. Biologic characterization of adult MYC-translocation positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 2014; 99:726-735.
36. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121:2253-2263.
37. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44:1321-1325.
38. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitts lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419-2430.
39. Valentino C, Kendrick S, Johnson N, et al. Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am J Clin Pathol 2013; 139:242-254.
40. Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol 2013; 162:40-49.
41. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44:1316-1320.
42. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490:116-120.
43. Basso K, Margolin AA, Stolovitzky G, et al. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37:382-390.
44. Seitz V, Butzhammer P, Hirsch B, et al. Deep sequencing of MYC DNAbinding sites in Burkitt lymphoma. PLoS One 2011; 6:e26837.
45. Walsh K, McKinney MS, Love C, et al. PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin Cancer Res 2013; 19:1106-1115.
46. Shortt J, Martin BP, Newbold A, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYCdriven B-cell lymphomas. Blood 2013; 121:2964-2974.
47. Fang X, Jiang Y, Feng L, et al. Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70. Cancer Cell Int 2013; 13:48.
48. Huang Y, Hu J, Zheng J, et al. Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 2012; 31:48.
49. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 2013; 8:e55119.
50. Zhang J, Grubor V, Love CL, et al. Genetic, heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110:1398-1403.
51. Garcia JL, Hernandez JM, Gutierrez NC, et al. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitts lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 2003; 17:2016-2024.
52. Salaverria I, Zettl A, Beà S, et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitts lymphoma. Haematologica 2008; 93:1327-1334.
53. Roug AS, Wendtland P, Bendix K, Kjeldsen E. Supernumerary isochromosome 1, idic(1)(p12), leading to tetrasomy 1q in Burkitt lymphoma. Cytogenet Genome Res 2014; 142:7-13.
54. Schiffman JD, Lorimer PD, Rodic V, et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol 2011; 155:477-486.
55. Havelange V, Ameye G, Théate I, et al. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement. Genes Chromosomes Cancer 2013; 52:81-92.
56. Scholtysik R, Nagel I, Kreuz M, et al. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13. 3 in diffuse large B-cell and Burkitt lymphomas. Int J Cancer 2012; 131:E830-E835.